A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast Cancer
Conditions
Breast Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Gustave Roussy, Villejuif, France
Contact: Study coordinator (Jean Zeghondy, MD) · Jean.ZEGHONDY@gustaveroussy.fr · + 33 01 42 11 42 11